13 June 2013Americas

US Supreme Court strikes Myriad blow

The US Supreme Court has ruled that isolated human DNA is not patent eligible and has struck down patents owned by biotech company Myriad, ending a long-running and controversial case.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Myriad decision applied in diagnostic claims case

6 November 2013 The US District Court for the Northern District of California has found that diagnostic claims covering conventional detection methods do not make the use of a natural phenomenon patent eligible.

Myriad faces yet another patent battle

28 November 2013 Genetic diagnostics company Invitae Corporation has requested declaratory judgment at the US District Court for the Northern District of California that it does not infringe 11 patents owned or exclusively licensed to Myriad Genetics.

Cantor Colburn tops list of law firms overturning Myriad rejections

25 August 2017 Law firm Cantor Colburn has achieved the highest rate of successful allowances for patent applications following section 101 rejections citing the Mayo and Myriad precedents, according to data compiled by research firm Juristat.

More on this story

Myriad decision applied in diagnostic claims case

6 November 2013 The US District Court for the Northern District of California has found that diagnostic claims covering conventional detection methods do not make the use of a natural phenomenon patent eligible.

Myriad faces yet another patent battle

28 November 2013 Genetic diagnostics company Invitae Corporation has requested declaratory judgment at the US District Court for the Northern District of California that it does not infringe 11 patents owned or exclusively licensed to Myriad Genetics.

Cantor Colburn tops list of law firms overturning Myriad rejections

25 August 2017 Law firm Cantor Colburn has achieved the highest rate of successful allowances for patent applications following section 101 rejections citing the Mayo and Myriad precedents, according to data compiled by research firm Juristat.

More on this story

Myriad decision applied in diagnostic claims case

6 November 2013 The US District Court for the Northern District of California has found that diagnostic claims covering conventional detection methods do not make the use of a natural phenomenon patent eligible.

Myriad faces yet another patent battle

28 November 2013 Genetic diagnostics company Invitae Corporation has requested declaratory judgment at the US District Court for the Northern District of California that it does not infringe 11 patents owned or exclusively licensed to Myriad Genetics.

Cantor Colburn tops list of law firms overturning Myriad rejections

25 August 2017 Law firm Cantor Colburn has achieved the highest rate of successful allowances for patent applications following section 101 rejections citing the Mayo and Myriad precedents, according to data compiled by research firm Juristat.

More features

Bayer gains exclusive licence for heart drug in Japan

EPO delivers key Novo Nordisk, GSK and Inhibrx rulings

McGuireWoods expands team with ex-Novo Nordisk GC

Paul, Weiss swoops for senior duo from Weil, Gotshal

UPC bans Meril Life Sciences from selling infringing heart valve

SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic

Kathi Vidal to rejoin previous firm as partner following USPTO departure

GSK triumphs in EPO appeal, revoking Pfizer patent